We are live on ! Find out more
CC

Caxton Corporation Portfolio holdings

AUM $4.02M
1-Year Est. Return 256.08%
This Fund
S&P 500
This Quarter Est. Return
+5.84%
1 Year Est. Return
+256.08%
3 Year Est. Return
+777.99%
5 Year Est. Return
+744.68%
10 Year Est. Return
+18,621.85%
AUM
$154M
AUM Growth
-$6.48M
Cap. Flow
+$6.05M
Cap. Flow %
3.93%
Top 10 Hldgs %
81.82%
Holding
74
New
30
Increased
23
Reduced
8
Closed
5

Top Buys

Rank Stock Value
1
SVRA icon
Savara
SVRA
+$9.84M
2
KALA icon
KALA BIO
KALA
+$2.26M
3
LUXA
Lux Health Tech Acquisition Corp. Class A Common Stock
LUXA
+$2.22M
4
AAC.U
Ares Acquisition Corporation Units, each consisting of one Class A ordinary share, and one-fifth of one redeemable warrant
AAC.U
+$1.46M
5
ENJY
Enjoy Technology, Inc. Common Stock
ENJY
+$1.09M

Top Sells

Rank Stock Value
1
SPRU icon
Spruce Power Holding Corp
SPRU
+$7.12M
2
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
+$4.03M
3
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
+$3.17M
4
LUXAU
Lux Health Tech Acquisition Corp. Units
LUXAU
+$2.3M
5
CZOO
Cazoo Group Ltd
CZOO
+$1.65M

Sector Composition

Rank Sector Weight
1 Healthcare 81.45%
2 Financials 4.57%
3 Communication Services 1.64%
4 Consumer Discretionary 1.29%
5 Technology 1.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MTEM
1
DELISTED
Molecular Templates, Inc.
MTEM
$26.8M 17.4%
141,533
– –
SBBP
2
DELISTED
Strongbridge Biopharma plc.
SBBP
$22.3M 14.49%
8,083,442
-6,000
-0.1% -$18.1K
CRDF icon
3
Cardiff Oncology
CRDF
$64.3M
$19.6M 12.72%
2,114,840
– –
SVRA icon
4
Savara
SVRA
$1.13B
$12M 7.77%
+5,752,215
New +$9.84M
SCYX icon
5
SCYNEXIS
SCYX
$37M
$11.2M 7.26%
175,986
-8,310
-5% -$545K
KALA icon
6
KALA BIO
KALA
$11.8M
$9.64M 6.26%
573
+116
+25% +$2.26M
SRRA
7
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$7.65M 4.97%
443,959
-200,000
-31% -$3.17M
CTIC
8
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$7.32M 4.75%
2,514,647
-1,235,243
-33% -$4.03M
GLD icon
9
SPDR Gold Trust
GLD
$132B
$6.53M 4.24%
40,820
-341
-0.8% -$57.3K
RZLT icon
10
Rezolute
RZLT
$480M
$3M 1.95%
424,243
– –
ADXN
11
Addex Therapeutics
ADXN
$7.45M
$2.79M 1.81%
13,297
– –
LUXA
12
DELISTED
Lux Health Tech Acquisition Corp. Class A Common Stock
LUXA
$2.05M 1.33%
+200,000
New +$2.22M
AAC.U
13
DELISTED
Ares Acquisition Corporation Units, each consisting of one Class A ordinary share, and one-fifth of one redeemable warrant
AAC.U
$1.42M 0.92%
+142,000
New +$1.46M
CZOO
14
DELISTED
Cazoo Group Ltd
CZOO
$1.11M 0.72%
54
-71
-57% -$1.65M
ENJY
15
DELISTED
Enjoy Technology, Inc. Common Stock
ENJY
$1.04M 0.68%
+105,500
New +$1.09M
ISEE
16
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$911K 0.59%
147,366
+12,385
+9% +$75.2K
HMCOU
17
DELISTED
HumanCo Acquisition Corp. Unit
HMCOU
$902K 0.59%
85,500
– –
EIGR
18
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$833K 0.54%
3,136
+501
+19% +$158K
BTWN
19
DELISTED
Bridgetown Holdings Limited Class A Ordinary Shares
BTWN
$680K 0.44%
62,688
-10,000
-14% -$138K
FLAC
20
DELISTED
Frazier Lifesciences Acquisition Corporation Class A Ordinary Shares
FLAC
$637K 0.41%
+64,000
New +$653K
BCIC
21
BCP Investment Corp
BCIC
$86.9M
$633K 0.41%
29,314
-595
-2% -$12K
SSAAU
22
DELISTED
Science Strategic Acquisition Corp. Alpha Unit
SSAAU
$616K 0.4%
+62,000
New +$637K
SCOAU
23
DELISTED
ScION Tech Growth I Unit
SCOAU
$588K 0.38%
58,500
– –
ONCS
24
DELISTED
OncoSec Medical Incorporated
ONCS
$553K 0.36%
+5,267
New +$721K
DIS icon
25
Walt Disney
DIS
$165B
$469K 0.3%
2,544
+674
+36% +$124K
1
2 3

Similar funds

PCM
Pathway Capital Management Irvine, California $4.3M AUM 62.8% 1-Year Est. Return
EAMS
Eurizon Asset Management Slovakia Bratislava $3.4M AUM
RCP
RPM Capital Partners New York $3.34M AUM 43.17% 1-Year Est. Return
RA
Ritter Alpha New York $4.78M AUM
CGA
Compound Global Advisors Mercer Island, Washington $3.22M AUM 30.08% 1-Year Est. Return
HFA
Harbert Fund Advisors Birmingham, Alabama $3.03M AUM 40.55% 1-Year Est. Return
ABA
American Beacon Advisors Irving, Texas $5.08M AUM 20.11% 1-Year Est. Return
UOMF
University of Maryland Foundation Adelphi, Maryland $5.1M AUM 10.69% 1-Year Est. Return

Caxton Corporation's Q1 2021 Portfolio in Review

As of Q1 2021, Caxton Corporation held 74 positions worth $154M, down 4% from $160M the previous quarter. Its ten largest holdings account for 82% of the portfolio.

Caxton Corporation deployed $6.05M of net new capital in Q1 2021, opening 30 new positions and adding to 23 existing holdings. Its largest new stake was Savara: 5,752,215 shares worth $12M.

By sector, the portfolio is most concentrated in Healthcare at 81% of assets, up from 81% a quarter earlier, followed by Financials and Communication Services.

On the sell side, the largest reduction was CTI BioPharma Corp. (DE) Common Stock, an estimated $4.03M trimmed.

  • Caxton Corporation's largest Q1 2021 buy was Savara: 5,752,215 shares worth $12M.
  • Caxton Corporation added most to KALA BIO in Q1 2021, an estimated $2.26M increase.
  • Caxton Corporation's biggest Q1 2021 reduction was CTI BioPharma Corp. (DE) Common Stock, cutting an estimated $4.03M.
  • Caxton Corporation fully exited Spruce Power Holding Corp in Q1 2021, selling an estimated $7.12M.
  • Caxton Corporation's ten largest holdings make up 82% of its $154M portfolio in Q1 2021.
  • Caxton Corporation opened 30 new positions and closed 5 in Q1 2021.
  • Caxton Corporation's portfolio value fell 4% quarter-over-quarter to $154M.

Based on Caxton Corporation's 13F filing for Q1 2021, filed 17 May 2021.